PHGE biomx.com: Long-Term Debt to Capital Coefficient

BiomX Inc. (PHGE) is scaling its bacteriophage platform, focusing on cystic fibrosis treatment following an expansion of assets. Success depends on the production stability of complex mixtures and the mitigation of resistance. The long-term debt-to-equity ratio trend confirms the financial strategy, where the 0.02 metric reflects current dynamics. This allows the company to diversify risks while developing therapies for skin and lung conditions.

BiomX Inc. maintains its leadership in the niche bacteriophage therapy segment due to the stability of its scientific core. This metric assesses the ratio of long-term debt to equity, determining financial leverage and the degree of dependence on creditors. The trend of long-term liabilities relative to the company's equity reflects the balance between debt financing and self-sufficiency. For BiomX Inc. (PHGE), low leverage is critical for retaining rare microbiologists through stock option programs. The stability of this indicator confirms the resilience of the business model during the clinical trial stage.